器官肿瘤晶片市场规模、份额和成长分析：按晶片结构、肿瘤模型类型、组成材料、应用、最终用户和地区划分－2026-2033年产业预测

2024 年全球器官肿瘤晶片市场价值为 9,990 万美元，预计到 2033 年将从 2025 年的 1.1538 亿美元增长到 3.6543 亿美元，预测期（2026-2033 年）的复合年增长率为 15.5%。

全球器官晶片市场的发展动力源自于製药业对创新解决方案的需求，以降低并加速药物研发风险。传统的二维细胞培养和动物模型往往无法充分模拟人类肿瘤的生理特性，因此，人们越来越依赖微工程肿瘤晶片系统，以提高转化准确性并最大限度地减少后期研发失败带来的高昂成本。微流体、3D生物列印技术和患者来源肿瘤模型的进步，正在推动开发更俱生理有效性的检测方法，从而改善临床决策。此外，人工智慧的整合透过提供自动化影像分析、整合分子数据和开发预测模型，提高了药物测试的准确性，有助于识别有前景的候选药物。这些技术的融合正在改变产业格局，并为癌症研究中的合作、标准化和减少对动物实验的依赖创造了重要机会。

全球器官肿瘤晶片市场的成长要素

全球器官肿瘤晶片市场正受到微流体技术显着进步的推动。该技术能够更精确地模拟天然组织结构和流体动态。这种生理相关性的提升增强了製药公司和学术研究人员对临床前模型的信心，并推动其在更有效的转化应用中得到应用。除了整合感测器和成像技术外，可容纳多种细胞类型的模组化设计也促进了广泛的研究活动和合作研究。因此，相关人员正不断投入资源并建立伙伴关係，以利用这些创新能力进行药物筛检、机制阐明和生物标记发现，所有这些都推动了市场成长。

全球器官肿瘤晶片市场的限制因素

全球器官肿瘤晶片市场面临诸多限制因素，其中之一便是开发、检验和规模化这些创新平台的高成本。对于小规模的实验室和新兴生物技术公司而言，对专业製造设施、严格的品管措施以及专业知识的需求，会导致初始投资增加和营运流程复杂化，从而造成沉重的财务负担。这种复杂性往往促使机构进行冗长的内部评估并采取谨慎的采购方式，减缓了新技术的应用。因此，这些财务和营运方面的挑战限制了市场渗透率，阻碍了器官肿瘤晶片解决方案的广泛应用，儘管其优势已得到科学证实。

全球器官肿瘤晶片市场趋势

全球器官肿瘤晶片市场正呈现出显着的整合趋势，即与药物开发平臺相融合，从而显着提升药物发现和优化过程的精准度。这些创新平台透过提供与现有筛检方法紧密结合的、与人体相关的模型，实现了更精确的预测分析。器官晶片开发商与药物研究人员之间日益密切的合作，使得迭代测试和化合物相互作用及作用机制的深入研究成为可能。这种合作模式不仅促进了转化研究，还加速了候选化合物的筛选，推动了工程创新与治疗目标融合的伙伴关係，并最终推动了癌症治疗策略在业界的演进。

目录

介绍

• 调查目的
• 市场定义和范围

调查方法

• 研究过程
• 二级资料和一级资料的方法
• 市场规模估算方法

执行摘要

• 全球市场展望
• 市场主要亮点
• 细分市场概览
• 竞争环境概述

市场动态及展望

• 总体经济指标
• 促进者和机会
• 抑制因素和挑战
• 供给面趋势
• 需求面趋势
• 波特的分析和影响

关键市场分析

• 关键成功因素
• 影响市场的因素
• 主要投资机会
• 生态系测绘
• 2025年市场魅力指数
• PESTLE分析
• 监理情势

全球器官肿瘤晶片市场规模：以晶片结构

• 单通道晶片
• 多通道/整合器官系统

全球器官肿瘤晶片市场规模：依肿瘤模型类型划分

• Lung Cancer-on-a-chip
• Breast Cancer-on-a-chip
• 大肠直肠癌和肝癌模型

全球器官肿瘤晶片市场规模：依组件材料划分

• 聚二甲基硅氧烷（PDMS）基体
• 热塑性树脂/水凝胶平台

全球器官肿瘤晶片市场规模：按应用领域划分

• 药物发现和疗效测试
• 个人化癌症治疗（患者来源细胞）
• 毒理学和安全性评估
• 癌症基础研究与转移研究

全球器官肿瘤晶片市场规模：依最终用户划分

• 药物和生物技术研发
• 学术研究机构
• 受託研究机构（CRO）

全球器官肿瘤晶片市场规模：按地区划分

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太国家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲国家

竞争资讯

• 前五大公司对比
• 主要企业2025年的市场定位
• 主要市场公司采取的策略
• 近期市场趋势
• 企业市场占有率分析，2025 年
• 主要企业的完整公司简介
  • 公司详情
  • 产品系列分析
  • 按细分市场进行企业市占率分析
  • 销售收入年比比较（2023-2025 年）

主要企业简介

• Emulate Inc.
• Mimetas
• InSphero AG
• TissUse GmbH
• Organovo
• Axosim
• Beonchip
• BioIVT
• Nortis Inc.
• CN Bio Innovations
• Hesperos Inc.
• AlveoliX
• Dynamic42
• Netri
• MesoBioTech
• SynVivo
• Cherry Biotech
• BiomimX
• Elveflow
• Fluigent

结论与建议

Global Organ Tumor Chip Market size was valued at USD 99.9 Million in 2024 and is poised to grow from USD 115.38 Million in 2025 to USD 365.43 Million by 2033, growing at a CAGR of 15.5% during the forecast period (2026-2033).

The global organ tumor chip market is driven by the pharmaceutical industry's demand for innovative solutions to de-risk and expedite drug development. Traditional two-dimensional cell cultures and animal models are often inadequate in mimicking human tumor physiology, prompting an increasing reliance on microengineered tumor-on-chip systems that enhance translational accuracy and minimize costly late-stage failures. With advancements in microfluidics, 3D bioprinting, and patient-derived tumor models, these technologies foster more physiologically relevant assays that improve clinical decision-making. Additionally, the integration of AI enhances drug testing accuracy by providing automated image analyses, integrating molecular data, and developing predictive models that help identify promising drug candidates. This convergence of technologies is reshaping the landscape, leading to significant opportunities for collaboration, standardization, and the reduction of animal study dependence in oncology research.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Organ Tumor Chip market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Organ Tumor Chip Market Segments Analysis

Global organ tumor chip market is segmented by chip architecture, tumor model type, component material, application domain, end-user and region. Based on chip architecture, the market is segmented into Single-channel Chips and Multi-channel/Integrated Organ Systems. Based on tumor model type, the market is segmented into Lung Cancer-on-a-chip, Breast Cancer-on-a-chip and Colorectal/Liver Cancer Models. Based on component material, the market is segmented into PDMS (Polydimethylsiloxane) based and Thermoplastic/Hydrogel Platforms. Based on application domain, the market is segmented into Drug Discovery & Efficacy Testing, Personalized Cancer Medicine (Patient-derived cells), Toxicology & Safety Assessment and Basic Cancer Research & Metastasis Studies. Based on end-user, the market is segmented into Pharmaceutical & Biotech R&D, Academic Research Institutes and Contract Research Organizations (CROs). Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Organ Tumor Chip Market

The Global Organ Tumor Chip market is being propelled forward by significant advancements in microfluidic technology, which have allowed for the more accurate imitation of natural tissue structures and fluid dynamics. This heightened physiological authenticity boosts the trust that pharmaceutical companies and academic researchers place in preclinical models, driving their adoption for more effective translational applications. The incorporation of sensors and imaging technologies, along with modular designs that accommodate various cell types, fosters a wide range of research endeavors and collaboration. Consequently, stakeholders are increasingly committing resources and forming partnerships to harness these innovative capabilities for drug screening, mechanistic investigations, and biomarker discovery, all of which contribute to the market's growth.

Restraints in the Global Organ Tumor Chip Market

The Global Organ Tumor Chip market faces considerable restraints due to high costs linked to the development, standardized validation, and scaling of these innovative platforms. Smaller research laboratories and emerging biotech companies may struggle with the financial demands, as the requirement for specialized fabrication facilities, stringent quality control measures, and expertise increases initial investments and complicates operational processes. This complexity tends to slow down the adoption of new technologies, as institutions often engage in prolonged internal evaluations and adopt cautious procurement approaches. Consequently, these financial and operational challenges limit market penetration and impede the widespread acceptance of organ tumor chip solutions, despite their proven scientific benefits.

Market Trends of the Global Organ Tumor Chip Market

The Global Organ Tumor Chip market is witnessing a significant trend toward integration into pharmaceutical development pipelines, enhancing the precision of drug discovery and optimization processes. By offering human-relevant models that align closely with existing screening practices, these innovative platforms facilitate more accurate predictive analyses. The collaboration between organ chip developers and pharmaceutical researchers is expanding, enabling iterative testing and deeper investigations into compound interactions and mechanisms. This collaborative approach not only bolsters translational research but also accelerates candidate selection and fosters partnerships that harmonize engineering innovations with therapeutic objectives, ultimately driving the evolution of cancer treatment strategies in the industry.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Organ Tumor Chip Market Size by Chip Architecture & CAGR (2026-2033)

• Market Overview
• Single-channel Chips
• Multi-channel/Integrated Organ Systems

Global Organ Tumor Chip Market Size by Tumor Model Type & CAGR (2026-2033)

• Market Overview
• Lung Cancer-on-a-chip
• Breast Cancer-on-a-chip
• Colorectal/Liver Cancer Models

Global Organ Tumor Chip Market Size by Component Material & CAGR (2026-2033)

• Market Overview
• PDMS (Polydimethylsiloxane) based
• Thermoplastic/Hydrogel Platforms

Global Organ Tumor Chip Market Size by Application Domain & CAGR (2026-2033)

• Market Overview
• Drug Discovery & Efficacy Testing
• Personalized Cancer Medicine (Patient-derived cells)
• Toxicology & Safety Assessment
• Basic Cancer Research & Metastasis Studies

Global Organ Tumor Chip Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical & Biotech R&D
• Academic Research Institutes
• Contract Research Organizations (CROs)

Global Organ Tumor Chip Market Size & CAGR (2026-2033)

• North America (Chip Architecture, Tumor Model Type, Component Material, Application Domain, End-User)
  • US
  • Canada
• Europe (Chip Architecture, Tumor Model Type, Component Material, Application Domain, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Chip Architecture, Tumor Model Type, Component Material, Application Domain, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Chip Architecture, Tumor Model Type, Component Material, Application Domain, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Chip Architecture, Tumor Model Type, Component Material, Application Domain, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Emulate Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mimetas
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• InSphero AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TissUse GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organovo
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axosim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beonchip
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioIVT
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nortis Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CN Bio Innovations
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hesperos Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AlveoliX
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dynamic42
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Netri
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MesoBioTech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SynVivo
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cherry Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BiomimX
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elveflow
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fluigent
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations